Chronic Myeloproliferative Disorders

Common Name(s)

Chronic Myeloproliferative Disorders

Chronic myeloproliferative disorders are a group of slow-growing blood cancers in which the bone marrow makes too many abnormal red blood cells, white blood cells, or platelets, which accumulate in the blood. The type of myeloproliferative disorder is based on whether too many red blood cells, white blood cells, or platelets are being made. Sometimes the body will make too many of more than one type of blood cell, but usually one type of blood cell is affected more than the others are.

There are 6 types of chronic myeloproliferative disorders: chronic myelogenous leukemia (CML), polycythemia vera, primary myelofibrosis (also called chronic idiopathic myelofibrosis), essential thrombocythemia, chronic neutrophilic leukemia, and chronic eosinophilic leukemia. Chronic myeloproliferative disorders sometimes become acute leukemia, in which too many abnormal white blood cells are made.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Chronic Myeloproliferative Disorders" for support, advocacy or research.

Logo
MPDSUPPORT.ORG

Since 1994, our MPD-SUPPORT web site and free support email list offers interesting information on chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, myelodysplasia, and myelofibrosis. Anyone - patient, family member, or health professional, is welcome to join our growing list of subscribers. Our archives are available for you to research information.

Last Updated: 14 Jan 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Chronic Myeloproliferative Disorders" for support, advocacy or research.

Logo
MPDSUPPORT.ORG

Since 1994, our MPD-SUPPORT web site and free support email list offers interesting information on chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, myelodysplasia, and myelofibrosis. Anyone - patient, family member, or health professional, is welcome to join our growing list of subscribers. Our archives are available for you to research information.

http://www.mpdsupport.org

Last Updated: 14 Jan 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Chronic Myeloproliferative Disorders" returned 65 free, full-text research articles on human participants. First 3 results:

Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis.
 

Author(s): Süleyman Karaköse, Nevin Oruç, Melia Zengin, Ulus Salih Akarca, Galip Ersöz

Journal: Turk J Gastroenterol. 2015 Jan;26(1):42-8.

 

The diagnosis of an underlying myeloproliferative neoplasm (MPN) is often problematic in patients with Budd Chiari syndrome (BCS) or portal vein thrombosis (PVT). This study aimed to assess the diagnostic value of the JAK2 gene V617F gain-of-function mutation for MPN in splanchnic ...

Last Updated: 20 Feb 2015

Go To URL
Splanchnic vein thrombosis, the onset manifestation in JAK positive Chronic Myeloproliferative Disorders Neoplasms.
 

Author(s): A M Vladareanu, V Popov, H Bumbea, M Onisai, A Ilea, C Dobrea, M Miulescu

Journal: J Med Life. ;4(1):97-101.

 

Patients with Myeloproliferative Neoplasms-(MPN) have a high risk of thrombotic complications. Portal vein thrombosis is a severe complication, which in many cases, appears at the onset of the disease; the risk factors are related to the presence of qualitatively altered thrombocytes ...

Last Updated: 20 Apr 2011

Go To URL
Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders.
 

Author(s): Sudha Sazawal, Jyoti Bajaj, Sunita Chikkara, Sonal Jain, Rahul Bhargava, Manoranjan Mahapatra, Renu Saxena

Journal: Indian J. Med. Res.. 2010 Oct;132():423-7.

 

The Janus-associated Kinase-2 mutation JAK2 V617F in chronic myeloproliferative disorders (CMPDs) has been described as a frequent genetic event in majority of patients with polycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF). Its frequency varies ...

Last Updated: 22 Oct 2010

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Chronic Myeloproliferative Disorders" returned 12 free, full-text review articles on human participants. First 3 results:

Pulmonary hypertension in patients with chronic myeloproliferative disorders.
 

Author(s): Y Adir, M Humbert

Journal: Eur. Respir. J.. 2010 Jun;35(6):1396-406.

 

Pulmonary hypertension (PH) is a severe haemodynamic disorder in which the pulmonary artery pressure is persistently elevated, leading to right-sided heart failure and death. Recently, chronic myeloproliferative diseases associated with pulmonary hypertension were included in the ...

Last Updated: 1 Jun 2010

Go To URL
Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders.
 

Author(s): Hui-Chi Hsu

Journal: J Chin Med Assoc. 2007 Mar;70(3):89-93.

 

The molecular pathogenesis of chronic myeloproliferative disorders (MPDs) is poorly understood. The hematopoietic progenitor cells of patients with polycythemia vera (PV) or essential thrombocythemia (ET) are characterized by hypersensitivity to hematopoietic growth factors and formation ...

Last Updated: 28 Mar 2007

Go To URL
The chronic myeloproliferative disorders and mutation of JAK2: Dameshek's 54 year old speculation comes of age.
 

Author(s): Kenneth Kaushansky

Journal: Best Pract Res Clin Haematol. 2007 Mar;20(1):5-12.

 

In 1951, William Dameshek speculated on the common origin of the chronic myeloproliferative disorders--polycythemia vera (PV), essential thrombocythemia (ET), chronic idiopathic myelofibrosis (IMF), and chronic myelogenous leukemia (CML). Subsequent work suggested that all arose from ...

Last Updated: 5 Mar 2007

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms
 

Status: Recruiting

Condition Summary: Chronic Myeloproliferative Neoplasms

 

Last Updated: 3 Feb 2016

Go to URL
Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders
 

Status: Not yet recruiting

Condition Summary: Myeloproliferative Disorders; Polycythemia Vera; Essential Thrombocythemia; Myelofibrosis; Chronic Myeloid Leukemia

 

Last Updated: 21 Jan 2016

Go to URL
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
 

Status: Recruiting

Condition Summary: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Nonmalignant Neoplasm

 

Last Updated: 18 Nov 2013

Go to URL